SCHEMBL2352003

SCHEMBL2352003

CCC(Sc1ccccn1)C1=CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.41
EHMT1 Q9H9B1 1/20 0.41
APOBEC3G Q9HC16 1/20 0.41
HPGD P15428 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 1/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 5/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 2/20 0.36
TSHR P16473 1/20 0.36
GAA P10253 1/20 0.36
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18400230 0.75 EHMT2 (0.50) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL256693 0.74 EHMT2 (0.48) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL7812413 0.73 EHMT2 (0.47) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL9888690 0.69 EHMT2 (0.56) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL30495965 0.69 EHMT2 (0.56) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL10884242 0.69 EHMT2 (0.42) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL20261217 0.68 EHMT2 (0.45) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL2350528 0.68 EHMT2 (0.42) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL22446603 0.68 SMN1; SMN2 (0.41) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2
SCHEMBL5162362 0.67 HPGD (0.38) EHMT2EHMT1APOBEC3GHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190137-A1 METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS JACOBSON RICHARD MARTIN 2011-08-04 US disclosed
EP-1409440-A4 A METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS ROHM & HAAS (US) 2005-09-14 EP disclosed
US-20050065033-A1 Method to inhibit ethylene responses in plants JACOBSON RICHARD MARTIN (US) 2005-03-24 US disclosed
EP-1409440-A1 A METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS ROHM AND HAAS COMPANY (US) 2004-04-21 EP disclosed
WO-2002068367-A1 A METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS ROHM AND HAAS COMPANY (US) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050065033-A1 Method to inhibit ethylene responses in plants ERN1, CTH, CBS EHMT2 2387/4885EHMT1 2284/4885APOBEC3G 2807/4885
US-20110190137-A1 METHOD TO INHIBIT ETHYLENE RESPONSES IN PLANTS ERN1, CTH, CBR3 EHMT2 2346/4885EHMT1 2221/4885APOBEC3G 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.